Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill
them or deliver cancer-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different way to stop cancer cells from dividing so they stop growing or
die. Combining monoclonal antibody therapy with chemotherapy may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of rituximab plus fludarabine in treating
patients who have Waldenstrom's macroglobulinemia.